These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 31655907)

  • 1. UK Patients of Bangladeshi Descent with Crohn's Disease Respond Less Well to TNF Antagonists Than Caucasian Patients.
    Gadhok R; Gordon H; Sebepos-Rogers G; Baillie S; Akbar S; Abbott JE; Michael E; Ahmad OF; Cooper B; Lindsay JO
    Dig Dis Sci; 2020 Jun; 65(6):1790-1799. PubMed ID: 31655907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The phenotype and course of inflammatory bowel disease in UK patients of Bangladeshi descent.
    Goodhand JR; Kamperidis N; Joshi NM; Wahed M; Koodun Y; Cantor EJ; Croft NM; Langmead FL; Lindsay JO; Rampton DS
    Aliment Pharmacol Ther; 2012 Apr; 35(8):929-40. PubMed ID: 22404452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Infliximab in Crohn's Disease Patients with Prior Primary-Nonresponse to Tumor Necrosis Factor Antagonists.
    Clark-Snustad KD; Singla A; Lee SD
    Dig Dis Sci; 2019 Jul; 64(7):1952-1958. PubMed ID: 30815825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Timing of Thiopurine or Anti-TNF Initiation Is Associated with the Risk of Major Abdominal Surgery in Crohn's Disease: A Retrospective Cohort Study.
    González-Lama Y; Suárez C; González-Partida I; Calvo M; Matallana V; de la Revilla J; Magaz M; Bernardo C; Agudo B; Ibarrola P; Relea L; Arévalo J; Vera MI; Abreu L
    J Crohns Colitis; 2016 Jan; 10(1):55-60. PubMed ID: 26520164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early anti-TNF/immunomodulator therapy is associated with better long-term clinical outcomes in Asian patients with Crohn's disease with poor prognostic factors.
    Oh EH; Oh K; Han M; Seo H; Chang K; Lee SH; Kim GU; Song EM; Seo M; Lee HS; Hwang SW; Park SH; Yang DH; Kim KJ; Byeon JS; Myung SJ; Yang SK; Ye BD
    PLoS One; 2017; 12(5):e0177479. PubMed ID: 28542298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlations between skin lesions induced by anti-tumor necrosis factor-α and selected cytokines in Crohn's disease patients.
    Włodarczyk M; Sobolewska A; Wójcik B; Loga K; Fichna J; Wiśniewska-Jarosińska M
    World J Gastroenterol; 2014 Jun; 20(22):7019-26. PubMed ID: 24944497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.
    Absah I; Faubion WA
    Inflamm Bowel Dis; 2012 Aug; 18(8):1488-92. PubMed ID: 21882301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinctive histopathologic phenotype in resection specimens from patients with Crohn's disease receiving anti-TNF-α therapy.
    Schaeffer DF; Walsh JC; Kirsch R; Waterman M; Silverberg MS; Riddell RH
    Hum Pathol; 2014 Sep; 45(9):1928-35. PubMed ID: 25022570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors predicting the therapeutic response to infliximab during maintenance therapy in Japanese patients with Crohn's disease.
    Matsuoka K; Hamada S; Shimizu M; Nanki K; Mizuno S; Kiyohara H; Arai M; Sugimoto S; Iwao Y; Ogata H; Hisamatsu T; Naganuma M; Kanai T; Mochizuki M; Hashiguchi M
    PLoS One; 2018; 13(10):e0204632. PubMed ID: 30286108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Anti-TNF therapy in treatment of luminal Crohn's disease].
    Marko B; Prka L
    Acta Med Croatica; 2013 Apr; 67(2):179-89. PubMed ID: 24471301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients with perianal Crohn's fistulas experience delays in accessing anti-TNF therapy due to slow recognition, diagnosis and integration of specialist services: lessons learned from three referral centres.
    Lee MJ; Freer C; Adegbola S; Elkady S; Parkes M; Hart A; Fearnhead NS; Lobo AJ; Brown SR
    Colorectal Dis; 2018 Sep; 20(9):797-803. PubMed ID: 29569419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-tumor necrosis factor therapy decreases the risk of initial intestinal surgery after diagnosis of Crohn's disease of inflammatory type.
    Nagata Y; Esaki M; Moriyama T; Hirano A; Umeno J; Maehata Y; Torisu T; Matsumoto T; Kitazono T
    J Gastroenterol; 2019 Apr; 54(4):330-338. PubMed ID: 30244398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
    Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C
    Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-TNF Therapy Within 2 Years of Crohn's Disease Diagnosis Improves Patient Outcomes: A Retrospective Cohort Study.
    Ma C; Beilman CL; Huang VW; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    Inflamm Bowel Dis; 2016 Apr; 22(4):870-9. PubMed ID: 26818419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A virtual clinic increases anti-TNF dose intensification success via a treat-to-target approach compared with standard outpatient care in Crohn's disease.
    Srinivasan A; van Langenberg DR; Little RD; Sparrow MP; De Cruz P; Ward MG
    Aliment Pharmacol Ther; 2020 Jun; 51(12):1342-1352. PubMed ID: 32379358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adalimumab for maintenance of remission in Crohn's disease.
    Townsend CM; Nguyen TM; Cepek J; Abbass M; Parker CE; MacDonald JK; Khanna R; Jairath V; Feagan BG
    Cochrane Database Syst Rev; 2020 May; 5(5):CD012877. PubMed ID: 32413933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of medical therapy on patients with Crohn's disease requiring surgical resection.
    Fu YT; Hong T; Round A; Bressler B
    World J Gastroenterol; 2014 Sep; 20(33):11808-14. PubMed ID: 25206286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic Markers Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn's Disease.
    Barber GE; Yajnik V; Khalili H; Giallourakis C; Garber J; Xavier R; Ananthakrishnan AN
    Am J Gastroenterol; 2016 Dec; 111(12):1816-1822. PubMed ID: 27596696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to biologic therapy in Crohn's disease is improved with early treatment: an analysis of health claims data.
    Rubin DT; Uluscu O; Sederman R
    Inflamm Bowel Dis; 2012 Dec; 18(12):2225-31. PubMed ID: 22359399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease.
    Lindsay JO; Armuzzi A; Gisbert JP; Bokemeyer B; Peyrin-Biroulet L; Nguyen GC; Smyth M; Patel H
    Dig Liver Dis; 2017 Oct; 49(10):1086-1091. PubMed ID: 28826571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.